Is My Asset Licensable?
This is a good question...a question which lacks a simple answer without quite a bit of analysis. We audit out-licensing processes, and there are times when the answer is…
Menu
Biotech Showcase and JPM 2017: Wind, Rain, and Meetings
Yeah, it rained last week in San Francisco. But the rain did not stop untold thousands of us from gathering at the many hotels, watering holes, and coffee shops around…
Looking Backward, Looking Forward
I believe it is fair to say that 2016 was a bit unusual. Thinking about the terminology many of us learned last year leads us to that conclusion: snowflake,…
Some Comments On Marijuana
The recent elections in the United States is bringing many long-standing policies into question. And, the continued legalization of marijuana is one of them. At Lacerta Bio, we have consistently…
What Will a Trump Administration Mean for Our Industry?
Few of us will soon forget waking up in Cologne to the news that we will soon have a "President Trump" in the Oval Office in a few months. So,…
On Catamarans, Elections, and #BIOEurope
BIO Europe was, yet again, an excellent conference for Lacerta Bio. Having the US election on television screens in the Exhibition Hall made for some surreal moments and discussions. Not a…
Can We ESKAPE This Problem?
Can we ESKAPE the problem which may kill thousands of human beings over the next decades? First, what is ESKAPE? Initially coined by Dr. Louis Rice, ESKAPE is a handy acronym for…
University Technology Transfer: Change is Needed
A few weeks ago, we attended the first annual Commercializing Biotech Innovation Conference in Syracuse, New York. The conference was held in the very new Central New York Biotech Accelerator in Syracuse (which is…
Biosimilars: Do We Finally Have a Market?
Last month, the FDA announced their approval of Amjevita, a biosimilar to AbbVie's Humira. Humira posted global sales exceeding $14 billion in 2015, and its patents are set to expire in…
The $25 Coffee Mug
Our recent trip to Stockholm and the Nordic Life Science Days conference was quite enlightening, especially as we publicly discuss drug prices (yet again). One presentation at NLSD by SwedenBio enlightened us on how…
- Go to the previous page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- …
- 35
- Go to the next page